Network Pharmacology and Molecular Docking Study of the Chinese Miao Medicine Sidaxue in the Treatment of Rheumatoid Arthritis
Ning Wu,Taohua Yuan,ZhiXin Yin,Xiaotian Yuan,Jianfei Sun,Zunqiu Wu,Qilong Zhang,Carl Redshaw,Shenggang Yang,Xiaotian Dai
DOI: https://doi.org/10.2147/DDDT.S330947
2022-02-19
Abstract:Ning Wu, 1, &ast Taohua Yuan, 1, &ast ZhiXin Yin, 1 Xiaotian Yuan, 1 Jianfei Sun, 1 Zunqiu Wu, 1 Qilong Zhang, 1 Carl Redshaw, 2 Shenggang Yang, 1 Xiaotian Dai 3 1 Guizhou Medical University, Guiyang, Guizhou, People's Republic of China; 2 Department of Chemistry, University of Hull, Hull, Yorkshire, HU6 7RX, UK; 3 Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada &astThese authors contributed equally to this work Correspondence: Shenggang Yang, Guizhou Medical University, Guiyang, Guizhou, 550025, People's Republic of China, Tel/Fax +86 13158000576, Email Xiaotian Dai, Department of Mathematics and Statistics, University of Calgary, Calgary, AB, T2N 1N4, Canada, Tel/Fax +1 435 754 4980, Email Purpose: This study aimed to investigate the molecular mechanisms of Compound Sidaxue (SX), a prescription of Chinese Miao medicine, in treating rheumatoid arthritis (RA) using network pharmacology and in vivo experimental approaches. Methods: Network pharmacology was adopted to detect the active components of four Traditional Chinese herbal medicine (TCM) of SX, and the key targets and signaling pathways in the treatment of RA were predicted, and the key components and targets were screened for molecular docking. The predicted targets and pathways were validated in bovine type II collagen and incomplete Freund's adjuvant emulsifier-induced rat RA model. Results: In this study, we identified 33 active components from SX, predicted to act on 44 RA-associated targets by network pharmacology. PPI network demonstrated that TNF-α, VEGF-A, IL-2, IL-6, AKT, PI3K, STAT1 may serve as the key targets of SX for the treatment of RA. The main functional pathways involving these key targets include PI3K-AKT signaling pathway, TNF signaling pathway, NF-κB signaling pathway. Molecular docking analysis found that the active components β-amyrin, cajanin, eleutheroside A have high affinity for TNF-α, VEGFA, IL-2, AKT, and PI3K, etc. SX can improve joint swelling in Collagen-induced arthritis (CIA) rats, reduce inflammatory cell infiltration and angiogenesis in joint synovial tissue, and down-regulate IL-2, IL-6, TNF-α, VEGF, PI3K, AKT, p-AKT, NF-κBp65, the expression of p-NF-κBp65, STAT1, and PTGS2 are used to control the exacerbation of inflammation and alleviate the proliferation of synovial pannus, and at the same time play the role of cartilage protection to achieve the effect of treating RA. Conclusion: Through a network pharmacology approach and animal study, we predicted and validated the active compounds of SX and their potential targets for RA treatment. The results suggest that SX can markedly alleviate CIA rat by modulating the VEGF/PI3K/AKT signaling pathway, TNF-α signaling pathway, IL/NF-κB signaling pathway. Keywords: network pharmacology, molecular docking, rheumatoid arthritis, Sidaxue, VEGF/PI3K/AKT signaling pathway, TNF-α signaling pathway, IL/NF-κB signaling pathway Rheumatoid arthritis (RA) is a common type of chronic inflammatory autoimmune disease that primarily affects joints, but in severe cases, also affects internal organs, such as the lung, heart, and kidney. RA is clinically characterized by a sudden onset of chronic and progressive joint swelling, pain, and joint deformities, which gradually cause joint dysfunction and eventually disability. 1–3 RA, as a refractory disease, has the highest disability rate among all joint diseases, affecting between 0.5% and 1% of the global population, and is most common amongst the elderly. Further analysis reveals that the incidence for women is 2 to 3 times that of men, and is one of the main reasons for human loss of labor and disability. 1–3 At present, there is no clinically effective drug for the treatment of RA, and commonly used drugs have certain unwanted side effects. 4,5 For example, nonsteroidal anti-inflammatory drugs (NSAIDs), which are drugs that are commonly used to improve the symptoms of arthritis, have analgesic and anti-inflammatory effects, however they cannot control the development of the disease and have obvious gastrointestinal reactions. Moreover, they can increase the incidence of cardiovascular disease. Disease modifying anti-rheumatic drugs (DMARDs) have the effect of improving and delaying the progress of the disease. However, the onset is slow, and can take 1–6 months to be effective, and it is easy to cause liver, gastrointestinal, bone marrow problems, whilst the function of the kidneys and other organs can be impaired. Glucocorticoid (GC) has a great anti-inflammatory effect and can quickly relieve joint swelling and pa -Abstract Truncated-